SU-F-P-13: NRG Oncology Medical Physics Manpower Survey Quantifying Support Demands for Multi Institutional Clinical Trials

2016 ◽  
Vol 43 (6Part5) ◽  
pp. 3360-3361
Author(s):  
J Monroe ◽  
K Boparai ◽  
Y Xiao ◽  
D Followill ◽  
J Galvin ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Medical Physics

scholarly journals An overview of the medical-physics-related verification system for radiotherapy multicenter clinical trials by the Medical Physics Working Group in the Japan Clinical Oncology Group–Radiation Therapy Study Group

2020 ◽  
Vol 61 (6) ◽  
pp. 999-1008
Author(s):  
Teiji Nishio ◽  
Mitsuhiro Nakamura ◽  
Hiroyuki Okamoto ◽  
Satoshi Kito ◽  
Toshiyuki Minemura ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Radiation Therapy ◽  
Working Group ◽  
Medical Physics ◽  
Study Group ◽  
Oncology Group ◽  
Japan Clinical Oncology Group ◽  
The Absolute ◽  
Multicenter Clinical Trials ◽  
Physical Quantities

Abstract The Japan Clinical Oncology Group–Radiation Therapy Study Group (JCOG-RTSG) has initiated several multicenter clinical trials for high-precision radiotherapy, which are presently ongoing. When conducting multi-center clinical trials, a large difference in physical quantities, such as the absolute doses to the target and the organ at risk, as well as the irradiation localization accuracy, affects the treatment outcome. Therefore, the differences in the various physical quantities used in different institutions must be within an acceptable range for conducting multicenter clinical trials, and this must be verified with medical physics consideration. In 2011, Japan’s first Medical Physics Working Group (MPWG) in the JCOG-RTSG was established to perform this medical-physics-related verification for multicenter clinical trials. We have developed an auditing method to verify the accuracy of the absolute dose and the irradiation localization. Subsequently, we credentialed the participating institutions in the JCOG multicenter clinical trials that were using stereotactic body radiotherapy (SBRT) for lungs, intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT) for several disease sites, and proton beam therapy (PT) for the liver. From the verification results, accuracies of the absolute dose and the irradiation localization among the participating institutions of the multicenter clinical trial were assured, and the JCOG clinical trials could be initiated.

scholarly journals Nuclear Magnetic Resonance Imaging

1982 ◽  
Vol 35 (6) ◽  
pp. 761 ◽  
Author(s):  
JM Pope
Keyword(s):  
Magnetic Resonance Imaging ◽  
Nuclear Magnetic Resonance ◽  
Clinical Trials ◽  
Magnetic Resonance ◽  
Medical Physics ◽  
Nmr Imaging ◽  
Resonance Imaging ◽  
New Techniques ◽  
Nmr Methods ◽  
Nuclear Magnetic

The principles of two new techniques of medical physics, nuclear magnetic resonance (NMR) imaging and topical magnetic resonance, are outlined. Progress in the development of these techniques and their application in clinical trials is reviewed. Advantages of NMR methods over existing imaging modalities are discussed. Finally some safety aspects are considered.

scholarly journals NRG Oncology Survey on Practice and Technology Use in SRT and SBRT Delivery

2020 ◽  
Vol 10 ◽  
Author(s):  
Mikhail Chetvertkov ◽  
James Ira Monroe ◽  
Jaskaran Boparai ◽  
Timothy D. Solberg ◽  
Deanna H. Pafundi ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Technology Use ◽  
Medical Physics ◽  
Volumetric Modulated Arc Therapy ◽  
Target Volume ◽  
Motion Management ◽  
Lung Sbrt ◽  
Policies And Procedures ◽  
Delivery Technique ◽  
Set Up

PurposeTo assess stereotactic radiotherapy (SRT)/stereotactic body radiotherapy (SBRT) practices by polling clinics participating in multi-institutional clinical trials.MethodsThe NRG Oncology Medical Physics Subcommittee distributed a survey consisting of 23 questions, which covered general technologies, policies, and procedures used in the Radiation Oncology field for the delivery of SRT/SBRT (9 questions), and site-specific questions for brain SRT, lung SBRT, and prostate SBRT (14 questions). Surveys were distributed to 1,996 radiotherapy institutions included on the membership rosters of the five National Clinical Trials Network (NCTN) groups. Patient setup, motion management, target localization, prescriptions, and treatment delivery technique data were reported back by 568 institutions (28%).Results97.5% of respondents treat lung SBRT patients, 77.0% perform brain SRT, and 29.1% deliver prostate SBRT. 48.8% of clinics require a physicist present for every fraction of SBRT, 18.5% require a physicist present for the initial SBRT fraction only, and 14.9% require a physicist present for the entire first fraction, including set-up approval for all subsequent fractions. 55.3% require physician approval for all fractions, and 86.7% do not reposition without x-ray imaging. For brain SRT, most institutions (83.9%) use a planning target volume (PTV) margin of 2 mm or less. Lung SBRT PTV margins of 3 mm or more are used in 80.6% of clinics. Volumetric modulated arc therapy (VMAT) is the dominant delivery method in 62.8% of SRT treatments, 70.9% of lung SBRT, and 68.3% of prostate SBRT.ConclusionThis report characterizes SRT/SBRT practices in radiotherapy clinics participating in clinical trials. Data made available here allows the radiotherapy community to compare their practice with that of other clinics, determine what is achievable, and assess areas for improvement.

Localization of Gallium-67 in Peritoneal Cells by Electron Microscopic Autoradiography

1973 ◽  
Vol 31 ◽  
pp. 404-405
Author(s):  
D. C. Swartzendruber ◽  
Norma L. Idoyaga-Vargas
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Tumor Tissue ◽  
Soft Tissue Tumors ◽  
Clinical Usefulness ◽  
Electron Microscopic ◽  
Normal Cells ◽  
Electron Microscopic Autoradiography ◽  
Peritoneal Cells ◽  
Gallium 67

The radionuclide gallium-67 (67Ga) localizes preferentially but not specifically in many human and experimental soft-tissue tumors. Because of this localization, 67Ga is used in clinical trials to detect humar. cancers by external scintiscanning methods. However, the fact that 67Ga does not localize specifically in tumors requires for its eventual clinical usefulness a fuller understanding of the mechanisms that control its deposition in both malignant and normal cells. We have previously reported that 67Ga localizes in lysosomal-like bodies, notably, although not exclusively, in macrophages of the spocytaneous AKR thymoma. Further studies on the uptake of 67Ga by macrophages are needed to determine whether there are factors related to malignancy that might alter the localization of 67Ga in these cells and thus provide clues to discovering the mechanism of 67Ga localization in tumor tissue.

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I

Clinical trials screening: An opportunity to increase medical care access

2001 ◽  
Vol 120 (5) ◽  
pp. A410-A410
Author(s):  
T KOVASC ◽  
R ALTMAN ◽  
R JUTABHA ◽  
G OHNING
Keyword(s):  
Clinical Trials ◽  
Medical Care ◽  
Care Access
Sign in / Sign up

Export Citation Format

Share Document